Team:Purdue/Project

From 2009.igem.org

(Difference between revisions)
Line 9: Line 9:
-
{|align="justify"
+
== '''Abstract''' ==
-
|You can write a background of your team here.  Give us a background of your team, the members, etc.  Or tell us more about something of your choosing.
+
-
|[[Image:Example_logo.png|200px|right]]
+
-
|-
+
-
|''Tell us more about your project.  Give us background.  Use this is the abstract of your project.  Be descriptive but concise (1-2 paragraphs)''
+
-
|[[Image:Team.png|right]]
+
-
|-
+
-
|align="center"|[[Team:Purdue | Team Example 2]]
+
-
|}
+
-
<!--- The Mission, Experiments --->
+
Glioblastoma multiform (GBM) is one of the most common forms of primary brain cancer, which usually results in fatality. To date, it has been difficult to overcome primary brain cancer resulting from GBM, primarily because the cancer- initiating cells are suspected to be highly resistant to current cancer therapies. The present study, focused on CD133+ cells found in primary GBM samples. CD133+ cells have shown resistance to hypoxia, irradiation, and some forms of chemotherapy. CD133+ hunting machines are created by genetically engineering microglial cells (BV-2) with two constructs using mammalian expression vectors and taking advantage of inherent qualities of the microglia such as; constantly sensing the surrounding environment, and quick motility. The engineered BV-2s will be equipped to locate the specific GBMs and label the targeted cells with a tat-GFP fusion protein. To create an in vivo-like environment, the cells will be grown in 3D collagen media. This creates a maze and challenges the microglia to actually seek out the cancer cells. Cell sorting technique is used to measure the accuracy in hitting positive targets, CD133+ cells.  It is the goal of this study to show an alternative approach to cancer treatment, and to emphasize the power of biologically available options to fight the disease.
-
(''Or you can choose different headings.  But you must have a team page, a project page, and a notebook page.'')
 
-
 
-
 
-
 
-
== '''Overall project''' ==
 
-
 
-
Glioblastoma multiform (GBM) is one of the most common forms of primary brain cancer, which usually results in fatality. To date, it has been difficult to overcome primary brain cancer resulting from GBM, primarily because the cancer- initiating cells are suspected to be highly resistant to current cancer therapies. The present study, focused on CD133+ cells found in primary GBM samples. CD133+ cells have shown resistance to hypoxia, irradiation, and some forms of chemotherapy. CD133+ hunting machines are created by genetically engineering microglial cells (BV-2) with two constructs using mammalian expression vectors and taking advantage of inherent qualities of the microglia such as; constantly sensing the surrounding environment, and quick motility. The engineered BV-2s will be equipped to locate the specific GBMs and label the targeted cells with a tat-GFP fusion protein. To create an in vivo-like environment, the cells will be grown in 3D collagen media. This creates a maze and challenges the microglia to actually seek out the cancer cells. Cell sorting technique is used to measure the accuracy in hitting positive targets, CD133+ cells.  It is the goal of this study to show an alternative approach to cancer treatment, and to emphasize the power of biologically available options to fight the disease.
 
== Project Details==
== Project Details==

Revision as of 14:15, 17 September 2009

Header.png

Home The Team The Project Parts Submitted to the Registry Modeling Notebook


Contents

Abstract

Glioblastoma multiform (GBM) is one of the most common forms of primary brain cancer, which usually results in fatality. To date, it has been difficult to overcome primary brain cancer resulting from GBM, primarily because the cancer- initiating cells are suspected to be highly resistant to current cancer therapies. The present study, focused on CD133+ cells found in primary GBM samples. CD133+ cells have shown resistance to hypoxia, irradiation, and some forms of chemotherapy. CD133+ hunting machines are created by genetically engineering microglial cells (BV-2) with two constructs using mammalian expression vectors and taking advantage of inherent qualities of the microglia such as; constantly sensing the surrounding environment, and quick motility. The engineered BV-2s will be equipped to locate the specific GBMs and label the targeted cells with a tat-GFP fusion protein. To create an in vivo-like environment, the cells will be grown in 3D collagen media. This creates a maze and challenges the microglia to actually seek out the cancer cells. Cell sorting technique is used to measure the accuracy in hitting positive targets, CD133+ cells. It is the goal of this study to show an alternative approach to cancer treatment, and to emphasize the power of biologically available options to fight the disease.


Project Details

Part 2

The Experiments

Part 3

Results

Retrieved from "http://2009.igem.org/Team:Purdue/Project"